| Expression pattern: |
DN |
| Associated gene: |
- |
| Associated microRNA: |
miR‐424 |
| Biological function: |
Elevates chemosensitivity to cisplatin and doxorubicin; associated with better histological response and prolonged DFS/OS in osteosarcoma. |
| Molecular mechanism: |
circ-LARP4 acts as a miRNA sponge for miR-424; miR-424 overexpression attenuates circ-LARP4-mediated chemosensitivity; direct binding supported by luciferase reporter assay. |
| Biological pathway or process: |
ceRNA regulation (promotes); drug resistance (inhibits); chemoresistance (inhibits) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Clinical Sample Validation; Transfection; CCK8; Luciferase Reporter Assay; ROC Analysis; Survival Analysis |
| Clinical significance: |
Lower in tumor vs non-tumor tissue; distinguishes tumor from non-tumor (AUC 0.829); high tumor circ-LARP4 correlates with decreased Enneking stage, increased good histological response (TCNR ≥90%), and prolonged DFS/OS. |
| Description: |
circ-LARP4 is down-regulated in osteosarcoma tumor tissue and serves as a favorable biomarker: higher tumor expression associates with lower Enneking stage, better histological response, and longer DFS/OS. Functionally, circ-LARP4 overexpression increases chemosensitivity (notably to cisplatin and doxorubicin) by sponging miR-424, supported by rescue and luciferase assays. |
| Confidence score: |
0.7445 |